Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 4, 1994 - Issue 6
Submit an article Journal homepage
13
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Patent Update Biologicals & Immunologicals: DNA topoisomerase inhibitors: potential uses in molecular medicine

Asit K Chakraborty Creighton Cancer Center, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE, 68178, USA
,
Hemanta K Majumder Indian Institute of Chemical Biology (CSIR), Calcutta, 700032, India
&
Clague P Hodgson Creighton Cancer Center, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE, 68178, USA
Pages 655-668 | Published online: 03 Mar 2008

References to Primarv Literaturess

  • WANG JC: DNA topoisomerases. Ann. Rev. Biochem.(1985) 54:665–697.
  • GELLERT M: DNA topoisomerases. Ann. Rev. Biochem.(1981) 50:879–910.
  • REECE RJ, MAXWELL A: DNA gyrase: structure and func-tion. Crit. Rev. Biochem. MoL Biol. (1991) 26(30-4):335–375.
  • DRLICA K, FRANCO RJ: Inhibitors of DNA topoisom- erases. Biochemistry (1988) 27(7):2253–2259.
  • LIU LF: DNA topoisomerase poisons as antitumour drugs. Ann. Rev. Biochem. (1989) 58:351–375.
  • D'ARPA P, LIU LF: Topoisomerase-targeting antitumour drugs. Biochem. Biophys. Acta. (1989) 989:163–177.
  • BRYSKIER A: Fluoroquinolones: mechanisms of action and resistance. Int.J. Antimicrob. Agents (1993) 2:151–184.
  • SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC, KAUFMANN SH: The current status of captothedn ana-logues as antitumour agents. J. Natl. Cancer. Inst. (1993) 85(4): 271–291.
  • HSIANG YH, HERTZBERG R, HECHT S, LIU LF:Carntothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase L J. Biol. Chem. (1985) 260:14873–14878.
  • ANDREA JE, ADACHI K, MORGAN AR: Fluorome1ric as-says for DNA topoisomerases and topoisomerase-tar-geted drugs: quantitation of catalytic activity and DNA cleavage. Mol. Pharmacol. 1991, 40(4):495–501.
  • YOSHIDA H, NAKAMURA M, BOGAKI M, ITO H, KOJIMA T, HATTORI H, NAICAO S: Mechanism of action of qui-nolones against Escbericbia coli DNA gyrase. Antimi-crob. Agents. Chemother. 1993, 37(4):839–845.
  • ARAKI K, KURODA T, UEMORI S, MORIGUCHI A, IKEDA Y, HIRAYAMA F, YOKOYAMA Y, IWAO E, YAKUSHIJI: Qui-nolone antimicrobial agents substituted with mor-pholines at the 7-position: synthesis and structure-activity relationships. J. Med. Chem. (1993) 36:1356–1363.
  • DOMAGALA JM, HAGEN SE, JOANNIDES T, KIELY JS, LABORDE E, SCHROEDER MC, SESNIE JA, SHAPIRO MA, SUTO KJ, VANDERROEST S: Quinolone antibacterials containing the new 7-[341-amilloelllY0- side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in Vivo efficacy. J. Med.Chem. (1993) 36:871–882.
  • LABORDE E, KIELY JS, CULBERTSON TP, LESHESKI LE: Quinolone antlbacterials: synthesis and biological ac-tivity of carbon isosteres of the 1-piperazinyl and 3-amino-l-pyrrolidinyl side chains. J. Med. Chem. (1993) 36:1964–1970.
  • BARRETT JF, GOOTZ TD, MCGUIRK PR, FARRELL CA, SOKOLOWSKI SA: Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. An-timicrob. Agents. Chemother. (1989) 33(10):1697–1703.
  • ELSEA SH, OSHEROFF N, NMSS JL: Cytotoxicity of qui-nolones toward eukaryotic cells. Identification of topoi-somerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J. Biol. Chem. (1992) 267(19):13150–13153.
  • RAIBINSON MJ, MARTIN BA, GOOTZ TD, MCGUIRK PR, MOYNIHAN M, SUTCLLFFE JA, OSHEROFF N: Effects of quinolone derivatives on eukaryotic topoisomerase fl a novel mechanism for enhancement of enzyme-medi-ated DNA cleavage. J. Biol. Chem. (1991) 266(22):14585–14592.
  • YOSHINORI Y, ASHIZAWA T, MORIMOTO M, HOSOMI J,NAKANO H: Antitamour quinolones with mammalian topoisomerase U mediated DNA cleavage activity. Can-cer Res. (1992) 52:2818–2822.
  • KOHLBRENNER WE, WIDEBURG N, Nam'. D, SALDIVARA, CHU TW: Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothia-zoloquinolones A-65281 and A-65282. Antimicrob. Agents Chemother. (1992) 36(1):81–86.
  • CORBETT AH, GUERRY P, PFLLEGER P, OSHEROFF N: Apyrimido[1,6,a] benziraidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential. Antimicrob. Agents Chemother. (1993) 37(12):2599–2605.
  • FROELICH-AMMON SJ, MCGUIRK PR, GOOTZ TD, JEFSONMR, OSHEROFF N: Novel quinolones with activity against topolsomerase II: stereo specificity of the eulcaryotic enzyme. Antimicrob. Agents Chemother. (1993) 37(4):646–651.
  • BAIR KW: Cancer drug development: current researchand patents 1992 - Part 1. Curr. Opin. Ther. Patents (1993) 3(6):695–742.
  • TERADA T, FUJIMOTO K, NOMURA M, YAMASHITA J, WIERZBA K, YAMAZAKI R, SHIBATA J, SUGIMOTO Y, YAMADA Y: Antitumour agents: synthesis and biological activity of 413-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-0-demethy1-4- desoxy-podophyllotoxin as antitumour agents. J. Med. Chem. (1993) 36:1689–1699.
  • GONZALESPERDOMO M, DECASTRO SL, MEIRELLES MNSL,GOLDBERG S: Ttypanosonta cruzi proliferation and differentiation are blocked by topoisomerase-II inhibi-tors. Antimicrob. Agents Chemother. (1990) 34(9):1707–1714.
  • CHAVALITSHEWIINKOON P, WILAIRAT P, GAMAGE S, DENNY W, FIGGITT D, RALPH R: Structure-activity rela-tionships and modes of action of 9-anilinoacridines against chloroquine resistant Plasmodium falcipartstn in vitro. Antimicrob. Agents Chemother. (1993) 37(3):403–406.
  • HERTZBERG RP, JOHNSON RK: Antineoplastic agents.Ann. Reports Med. Chem. (1993) 28:167–175.
  • ONO K, IICEGANI Y, NISHIZAWA M, ANDOH T: Menogaril,an anthracycline derivative, inhibits DNA topolsom-erase II by stabilizing cleavable complex. Jap. J. Cancer Res. (1992) 83(9):1018–1023.
  • YAMASHITA Y, KAWADA SZ, NAKANO H: Induction ofmammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and oroboL Biochem. Pbarrn. (1990), 39(4):737–744.
  • MCCULLOUGH JE, MULLER MT, HOWELLS AJ, MAXWELL A,O'SULLIVAN J, SUMMERILL RS, PARKER WE, WELLS JS, BONNER DP, FERNANDES PD: Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase. J. Antibio. (Ja-pan) (1993) 46(3):526–530.
  • YOSHINORI Y KAWADA S, FUNJII N, NAKANO H: Induc-tion of mammalian DNA topoisomerase I and II medi- ated DNA cleavage by saintopin, a new antitumour agent from fungus. Biochemistry (1991) 30:5838–5845.
  • YAMASHITA Y, KAWADA SZ, FUZI N, NAKANO H: Induc-tion of mammalian DNA topoisomerase-II dependent DNA cleavage by antitumour antibiotic streptonigrin. Cancer Res. (1990) 50(18):5841–5844.
  • TORNALETTI S, ANDERSEN AU, CHRISTIANSEN K, PFDRINIAM: 8- methoxycaffine inhibition of drosophila DNA topoisomerase IL Biochim Biophys Acta 1992, 1131(1):30–
  • BASTOW ICF, BORT ID, FUKUSHIMA Y, ICASHIWADA Y, TANAKA T, NONAKA G, NISHIOKA I, LEE ICH: Inhibition of DNA topoisomerases by sanguiin 11-6, a cytotoxic dimeric ellagitannin from Sanguisorba Planta. Med. (1993) 59(3):240–245.
  • KADOTA S, TAKAMORI Y, NYEIN KN, KIKUCHI T, TANAKA K, IKIMOTO H: Constituents of the leaves of Woodfordia fruticosa km-s. 1. Isolation, structure, and proton and carbon-13 nuclear magnetic resonance signal assign-ments of woodfruticosin (woodfordin C), an inhibitor of deoxyribonucleic acid topoisomerase II. Chem. Pharm. Bull. (Tokyo) (1990) 38(10):2687–2697.
  • WALL ME, MANI MC, COOK CE: Plant antitumour agents. 1. The isolation and structure of camtothecin, a novel alkaloidal leukemia and tumour inhibitor from camp-totheca acuminata. J. Am. Chem. Soc. 1966, 88:3888–3890.
  • KUNIMOTO T, NITTA K, TANAKA T, UEHARA N, BABA H, TAKEUCHI M, YOKOKURA T, SAWADA S, MIYASAKA T, MUTAI M: Antiturnour activity of 7-ethy1-1044-(1-piperidino)-1-piperdino]carbonyloxy- camptothecin, against murine tumours. Cancer Res. 1987, 47:5944–5947.
  • KINGSBURY WD, BOEHM JC, JAICAS DR: Synthesis of water soluble (amino alkyl) camptothedn analogues: inhibition of topoisomerase I and antitumour activity. J. Med. Chem. 1991, 34:98–100.
  • CHEN AY, YU C, BODLEY A, PENG LF, LIU LF: A newmammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 1993, 53:1332–1337.
  • SUZUKI K, YAMAGUCHI H, MIYAZAKI S, NAGAI K: Topostin, a novel Inhibitor of mammalian DNA topoi-somerase I from flextbacter topostinus sp Nov. 1. taxonomy, and fermentation of producing strain. J. Antibio. (1990) 43(2):154–157.
  • CHEN AY, YU C, GATTO B, LIU LF: DNA Minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA (1993) 90(17):8131–8135.
  • CHAICRABORTY AK, MAJUMDER HK: Mode of action of pentavalent antimoniaLs: specific inhibition of type I DNA topoisomerase of Leisbnsana donovani. Biochem Biophys Res Commun (1988) 152(2):605–611.
  • FANG S-D, WANG L-K, HECHT SM: Inhibitors of DNA topoisomerase I isolated from the Roots of Zantboxy-lum tdtidum. J. Org. Chem. (1993) 58(19):5025–5027.
  • LI CJ, AVERBOUK L, PARDEE AB: Beta-lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J. Biol. Chem. (1993) 268(30):22463–22468.
  • SORENSEN BS, SINDING J, ANDERSEN AIL ALSNER J, JENSEN PB, WESTERGAARD 0: Mode of action of topol-somerase II-targeting agents at a specific DNA sequence.
  • GEWIRTZ DA, ORR MS, FORNARY FA, RANDOLPH JK, YALOWICH JC, RITKE MK, POVIRK LF, BUNCH RT: Disso-ciation between bulk damage to DNA and the antipro-lfferative action of teniposide (VM-26) ht. the MCF-7 breast tumour cell line: evidence for induction of gene specific damage and alterations in gene expression. Cancer Res. (1993), 53: 3547–3554.
  • HOPPER DC: Quitkolone mode of action: new aspects. Drugs 1993, 45\(suppl 3):8–14.
  • WILLMOTT CJR, MAXWELL A: A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antirni-crob. Agents. Chemother. (1993), 37(1):126–127.
  • CAMPAIN JA, PADMANABHAN R, HWANG J, GOTTESMAN MM, PASTAN I: Characterization of an unusual mutant of human melanoma cells resistance to drugs that Inhibit topoisomerase II. J. Cell. Physiol. (1993), 155(2):414–425.
  • WASSERMAN RA, AUSTIN CA, FISHER LM, WANG JC: Useof yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombi-nant human DNA topoisomerase Ha in yeast. CancerRes. (1993), 53:3591–3596.
  • SHIMADA Y, YOSHINO M, WAKUI A, NAKAO I, FUTATSUKIK, SAKATA Y, KAMBE M, TAGUCHI T, OGAWA N: Phase 11 study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. (1993), 11(5):909–913.
  • THOMPSON DS, HAINSWORTH JD, HANDE KR, HOLZMERMC, GRECO AI Prolonged administration of low dose, infusional etoposide in patients with etoposkle sensi-tive neoplasms: a Phase I/11 study.]. Clin. Oncol. (1993), 119(7):1322–1428.
  • PEIN F, PINKERTON R, TOURADE ME, BRUNAT-MENTIGNY M, LEVITT G, MARGUERIFIE G, RUBLE H, SOMMELET D, THYSS A, ZUCKER JM: Etoposide in relapsed or refrac-tory wilm's tumour: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J. Clin. Oncol. 1993, 11(8):1478–1481.
  • PODDEVIN B, RIOU JF, LAVELLE F, POMMIER Y: Dualtopoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumour agent in early clinical trials. Mol. Pharmacol. (1993) 44(4): 767–774.
  • LARSEN AK, GRONDARD L, COUPRIE J, DESOIZE B, CO-MOE L, JARDILLIER JC, RIOU JF: The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisimerase I and Biochem. Pharmacol. (1993) 46(8): 1403–1412.
  • LORICO A, LONG BH: Biochemical characterisation of elsamicin and other cournarin related antitumor agents as potent inhibiors of human topoisomerse IL Eur. J. Cancer (1993) 29A(14): 1985–1991.
  • MANUEL J, DENNY W, GAMAGE S, RANSIJN A, WOJCIK S, FIGGITT D, RALPH R: 9-Anilinacridines as potential antileishmanial agents. Antimicrob. Agents. Chemother. 1993, 37(5):991–996.
  • FIGGITT D, DENNY W, CHAVALITSHEWINKOON P, WILAI-RAT P, RALPH R: In Vitro Study of Anticancer Acridines as Potential Antitrypanosomal and AntitnalarialAgents. Antimicrob. Agents Chemother. 1992, 36(8)1644–1647.
  • RIOU G, DOUC-RASY S, KAYSER A: Inhibitors of trypano-some topoisomerases. Biochem. Soc. Trans. (1986), 14:496–499.
  • SHAPIRO TA: Inhibition of topoisomerases in African trypanosomes. Acta Trop. (Basel) (1993), 54:251–260.
  • CHAKRABORTY AK, MAJUMDER HK: Decatenation of kinetoplast DNA by an ATP-dependent DNA topoisom-erase from the kinetoplast hemoflagellate Leishmania donovani. Mol. Biochem. Parasitol. 1987, 26:215–224.
  • SHAPIRO TA, ENGLUND PT: Selective cleavage of kineto-plast DNA minicircles promoted by antbrypanosomal drugs. Proc. Natl. Acad. Sci. USA (1990) 87:950–954.
  • BELL CA, Dykstra CC, Naiman NA, Cory M, Fairly TA, Tidwell RR: Structure-activity studies of dicationically substi-tuted bisbenzimidazoles against Giardia lambita: cor-relation of antigiardial activity with DNA binding affinity and giardial topoisomerase II inhibition. An-timicrob. Agents Chemother. (1993) 37(12):2668–2673.
  • BASSINI C, BISMARA C, CARLESS° R, FERIANI A, GAVI-RAGHI G, MARCHIORO C, PERBONI A, SHAW RE, TAM-BURINI B, TARZIA G: Synthesis and antimicrobial activity of DNA-gyrase inhibiting derivative of 4-oxo-1,4,dihydro-3-pyridinecarboxylic add. Farmaco. (1993), 48(2):159–189. YOSHIDA T, MITSUHASHI S: Antibacterial activity of NM394, the active form of prodrug NM441. Antimicrob. Agents Chemother. (1993), 37(4):793–800. MUKHARJEE A, SEN S, AGARWAL K: Ciprofloxacln, mam-malian DNA topoisomerase type II poison In Vivo. Mutat. Res. (1992), 301(2):87–92. SCHRODER HC, MERZ H, STEFFt,N R, MULLER WE, SARIN PS, TRUMN S, SCHULZ J, EICH E: Differential in vitro anti HIV activity of natural ligroin. Z. Naturforsch. (1990), 45(11–12):1215-1221.

References to patent literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.